Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

Ulutas Med J. 2018; 4(3): 164-167


A Case of Acute Sterile Endophthalmitis after Intravitreal Dexamethasone

Manar Ahmad Aljebreen, Hasan Aldhibi.




Abstract
Cited by 0 Articles

Introduction: Intravitreal dexamethasone implant (IDI) has been recently introduced into clinical practice for the treatment of various ocular conditions including non-infectious uveitis and macular edema. Endophthalmitis following IDI is an uncommon and a serious complication.
Case Presentation: In this report, we present a case of sterile endophthalmitis following IDI in a fourteen-year-old female for whom IDI was indicated to treat uveitic cystoid macular edema, which was refractory to maximum systemic and local therapy. She presented within 24 hours following the implant insertion, complaining of only a decrease in vision. It was managed by emergent pars plana vitrectomy with the removal of the implant. This resulted in clinical improvement and resolution of the inflammation. Intravitreal and implant Gram stain and polymerase chain reaction came out negative. An IDI was implanted one year later without similar complications.
Conclusion: Our case showed that sterile endophthalmitis could occur following intravitreal dexamethasone injection. Repeated IDI does not seem to be contraindicated.

Key words: Acute Sterile Endophthalmitis, Intravitreal Dexamethasone






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.